Great Point Partners (SCYX) reports 9.99% beneficial stake in Scynexis

Rhea-AI Filing Summary

Great Point Partners, LLC, together with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, reports beneficial ownership of 4,076,068 shares of SCYNEXIS, Inc. common stock, representing 9.99% of the class based on 9,930,329 shares outstanding after a 1-for-8 stock split effective June 1, 2026.

The position is held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., including common shares and warrant shares limited by a 9.99% Beneficial Ownership Cap on warrant exercises. Great Point acts as investment manager to the funds; Dr. Jay and Ms. Nordahl may be deemed beneficial owners but each disclaims ownership except to the extent of pecuniary interest.

Key Figures

Beneficial ownership: 4,076,068 shares Percent of class: 9.99% Shares outstanding: 9,930,329 shares +5 more

8 metrics

Beneficial ownership 4,076,068 shares Shares of SCYNEXIS common stock beneficially owned by the reporting persons

Percent of class 9.99% Portion of SCYNEXIS common stock beneficially owned by the reporting persons

Shares outstanding 9,930,329 shares SCYNEXIS common shares outstanding used to compute ownership percentages

BVF Shares 623,233 shares Biomedical Value Fund holdings, 6.24% of SCYNEXIS common stock

BOVF Shares 321,059 shares Biomedical Offshore Value Fund holdings, 3.22% of SCYNEXIS common stock

Pre-Funded Warrants 1,093,744 shares Shares of SCYNEXIS common stock underlying Pre-Funded Warrants held

Additional Warrants 2,038,032 shares Shares of SCYNEXIS common stock underlying additional Warrants held

BVF Warrants exercisable 35,011 shares SCYNEXIS warrant shares exercisable by BVF under the Beneficial Ownership Cap

Key Terms

Beneficial Ownership Cap, Pre-Funded Warrants, Rule 13d-3, investment manager, +1 more

5 terms

Beneficial Ownership Cap regulatory

"As a result of the Beneficial Ownership Cap, 35,011 shares underlying such Warrants"

A beneficial ownership cap is a rule that limits how much of a company a single investor or related group can effectively control, even if legal ownership could be higher. Think of it as a speed limit for ownership that prevents any one party from accumulating a controlling stake; it matters to investors because it affects takeover risk, voting power, dilution, and potential returns by shaping who can influence corporate decisions.

Pre-Funded Warrants financial

"hold in the aggregate Pre-Funded Warrants to purchase 1,093,744 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Rule 13d-3 regulatory

"Such shares constitute 6.24% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3"

Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.

investment manager financial

"Great Point is the investment manager of BVF, and by virtue of such status"

beneficial owner financial

"may be deemed to be the beneficial owner of the BVF Shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

FAQ

What stake in SCYX does Great Point Partners report in this Schedule 13G/A?

Great Point Partners and related reporting persons report beneficial ownership of 4,076,068 shares of SCYNEXIS common stock, representing 9.99% of the outstanding class, based on 9,930,329 shares outstanding after a 1-for-8 stock split.

How is Great Point Partners’ SCYX ownership structured across its funds?

Biomedical Value Fund holds 623,233 SCYNEXIS shares and Biomedical Offshore Value Fund holds 321,059 shares. Both funds also hold warrants, with portions currently exercisable under the Beneficial Ownership Cap of 9.99% of outstanding shares.

What is the Beneficial Ownership Cap disclosed for SCYX warrants?

The warrants held by the reporting persons include a 9.99% Beneficial Ownership Cap, limiting exercises so that the holder and affiliates cannot beneficially own more than 9.99% of SCYNEXIS common stock immediately after any exercise.

How many SCYX warrant and pre-funded warrant shares are held by the reporting group?

The reporting persons hold Pre-Funded Warrants to purchase 1,093,744 SCYNEXIS shares and Warrants to purchase 2,038,032 shares. Due to the Beneficial Ownership Cap, only specified portions of these warrants are currently counted as beneficially owned.

Do Great Point, Dr. Jay, and Ms. Nordahl claim full beneficial ownership of SCYX fund shares?

Great Point, Dr. Jay, and Ms. Nordahl may be deemed beneficial owners of the funds’ SCYNEXIS shares through their roles, but each disclaims beneficial ownership of the BVF and BOVF shares except to the extent of respective pecuniary interests.

What percentages of SCYX are held by BVF and BOVF individually?

Biomedical Value Fund’s 623,233 shares equal 6.24% of SCYNEXIS common stock, and Biomedical Offshore Value Fund’s 321,059 shares equal 3.22%, each percentage computed in accordance with Rule 13d-3 using 9,930,329 shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 09:34 AM Accepted by SEC EDGAR 08/14/2026 - 09:33 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

SCYNEXIS, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

811292309

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 811292309

1

Names of Reporting Persons

Great Point Partners, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,076,068.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,076,068.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,076,068.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 811292309

1

Names of Reporting Persons

Dr. Jeffrey R. Jay, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,076,068.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,076,068.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,076,068.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 811292309

1

Names of Reporting Persons

Ms. Lillian Nordahl

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,076,068.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,076,068.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,076,068.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SCYNEXIS, Inc.
(b)	Address of issuer's principal executive offices: 1 Evertrust Plaza, 13th Floor, Jersey City, New Jersey 07302-6548
Item 2.
(a)	Name of person filing: Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated August 14, 2026, a copy of which is filed with this SCHEDULE 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830
(c)	Citizenship: Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 811292309
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,076,068
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 4,076,068
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 4,076,068 Item 4 The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 9,930,329 shares outstanding, which is based on 79,442,633 common shares outstanding as reported by the Issuer in its form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 11, 2026, and after giving effect to a 1 for 8 stock split which took effect on June 1, 2026. The reporting persons hold in the aggregate Pre-Funded Warrants to purchase 1,093,744 shares of Common Stock and Warrants to purchase 2,038,032 shares of Common Stock (together with the Pre-Funded Warrants referred to herein as the "Warrants"); however, the provisions of such Warrants restrict the exercise of such Warrants to the extent that, after giving effect to such exercise, the holder of the Warrants and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the "Beneficial Ownership Cap"). As a result, all 53,047 shares underlying such Warrants are beneficially owned by the reporting persons. Biomedical Value Fund, L.P. ("BVF") is the record holder of 623,233 shares of Common Stock (the "BVF Shares"). Such shares constitute 6.24% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BVF is the record holder of Warrants to purchase an additional 2,066,972 shares of Common Stock (the "BVF Warrants"). As a result of the Beneficial Ownership Cap, 35,011 shares underlying such Warrants are exercisable, which constitutes 0.35% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Great Point Partners, LLC ("Great Point") is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record holder of 321,059 shares of Common Stock (the "BOVF Shares"). Such shares constitute 3.22% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BOVF is the record holder of Warrants to purchase an additional 1,064,804 shares of Common Stock (the "BOVF Warrants"). As a result of the Beneficial Ownership Cap, 18,036 shares underlying such Warrants are exercisable, which constitutes 0.18% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl), as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. Notwithstanding the above, Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares except to the extent of their respective pecuniary interests.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 4.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Great Point Partners, LLC

Signature:	/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:	Dr. Jeffrey R. Jay, M.D - Senior Managing Member
Date:	08/14/2026

Dr. Jeffrey R. Jay, M.D.

Signature:	/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:	Dr. Jeffrey R. Jay, M.D
Date:	08/14/2026

Ms. Lillian Nordahl

Signature:	/s/ Ms. Lillian Nordahl
Name/Title:	Ms. Lillian Nordahl
Date:	08/14/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: August 14, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl